Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
October 10, 2024 08:00 ET
|
Samsung Bioepis
Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
Samsung Bioepis Presents Totality-of-the-Evidence Supporting Extrapolation of EPYSQLI™ (SB12; Eculizumab)’s Indication, at the European Society of Paediatric Nephrology (ESPN) 2024
September 23, 2024 02:00 ET
|
Samsung Bioepis
Samsung Bioepis Presents Totality-of-the-Evidence Supporting Extrapolation of EPYSQLI™ (SB12; Eculizumab)’s Indication, at the European Society of Paediatr
Pixalate Releases Q2 2024 Global Mobile Device Market Share Report: Apple iPhone Leads Globally (51%), Followed by Samsung, Huawei, & Xiaomi
August 21, 2024 17:14 ET
|
Pixalate
London, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Navitas Powers Expanded Samsung Galaxy Smartphone Portfolio
August 05, 2024 08:30 ET
|
Navitas Semiconductor Corporation
TORRANCE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC)...
Pixalate Releases Top 100 Connected TV (CTV) Bundle ID Rankings For Global Open Programmatic Ad Spend on Roku, Amazon Fire TV, Samsung Smart TV, and Apple TV in June 2024
July 17, 2024 13:20 ET
|
Pixalate Inc.
LONDON, July 17, 2024 (GLOBE NEWSWIRE) -- Pixalate, the market-leading fraud protection, privacy, and compliance analytics platform for Connected TV (CTV) and Mobile Advertising, today released the...
Standard Bots Secures $63M in Funding to Propel American Manufacturing Forward with AI-Driven Robotics
July 12, 2024 12:00 ET
|
Standard Bots
Standard Bots secures $63M to advance US manufacturing with AI-driven robotics, backed by General Catalyst, Amazon, and Samsung, serving clients like NASA.
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
July 11, 2024 08:00 ET
|
Samsung Bioepis
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
July 01, 2024 02:03 ET
|
Samsung Bioepis
PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the...
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
June 25, 2024 09:00 ET
|
Samsung Bioepis
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
June 14, 2024 03:00 ET
|
Samsung Bioepis
Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre